|
US7427606B2
(en)
|
1999-02-01 |
2008-09-23 |
University Of Virginia Patent Foundation |
Method to reduce inflammatory response in transplanted tissue
|
|
US7378400B2
(en)
|
1999-02-01 |
2008-05-27 |
University Of Virginia Patent Foundation |
Method to reduce an inflammatory response from arthritis
|
|
US6232297B1
(en)
|
1999-02-01 |
2001-05-15 |
University Of Virginia Patent Foundation |
Methods and compositions for treating inflammatory response
|
|
US7074801B1
(en)
*
|
2001-04-26 |
2006-07-11 |
Eisai Co., Ltd. |
Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
|
|
NZ556354A
(en)
|
2001-10-01 |
2008-10-31 |
Univ Virginia |
2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
|
|
US6914053B2
(en)
*
|
2002-09-09 |
2005-07-05 |
Cv Therapeutics, Inc. |
Adenosine A3 receptor agonists
|
|
WO2004086034A2
(en)
*
|
2003-03-28 |
2004-10-07 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
|
|
CA2532965C
(en)
|
2003-07-22 |
2013-05-14 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
|
PE20060272A1
(es)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
|
|
AU2005267706B2
(en)
|
2004-08-02 |
2011-12-08 |
University Of Virginia Patent Foundation |
2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
|
|
US7576069B2
(en)
|
2004-08-02 |
2009-08-18 |
University Of Virginia Patent Foundation |
2-polycyclic propynyl adenosine analogs having A2A agonist activity
|
|
WO2006023272A1
(en)
|
2004-08-02 |
2006-03-02 |
University Of Virginia Patent Foundation |
2-polycyclic propynyl adenosine analogs having a2a agonist activity
|
|
CA2585581A1
(en)
*
|
2004-11-22 |
2006-05-26 |
King Pharmaceuticals Research & Development Inc. |
Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
|
|
MX2007008781A
(es)
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
|
GB0505219D0
(en)
*
|
2005-03-14 |
2005-04-20 |
Novartis Ag |
Organic compounds
|
|
JP5042996B2
(ja)
*
|
2005-05-19 |
2012-10-03 |
ギリアード・パロ・アルト・インコーポレイテッド |
Ａ１アデノシンレセプターアゴニスト
|
|
US7514417B2
(en)
|
2005-05-19 |
2009-04-07 |
Cv Therapeutics, Inc. |
A1 adenosine receptor agonists
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
ATE497960T1
(de)
*
|
2005-10-13 |
2011-02-15 |
Cv Therapeutics Inc |
A1-adenosinrezeptoragonisten
|
|
US8178509B2
(en)
|
2006-02-10 |
2012-05-15 |
University Of Virginia Patent Foundation |
Method to treat sickle cell disease
|
|
US7589076B2
(en)
*
|
2006-05-18 |
2009-09-15 |
Pgx Health, Llc |
Substituted aryl piperidinylalkynyladenosines as A2AR agonists
|
|
US8188063B2
(en)
|
2006-06-19 |
2012-05-29 |
University Of Virginia Patent Foundation |
Use of adenosine A2A modulators to treat spinal cord injury
|
|
DE102007012645A1
(de)
*
|
2007-03-16 |
2008-09-18 |
Bayer Healthcare Ag |
Substituierte Imidazo- und Triazolopyrimidine
|
|
EP2144911A2
(en)
|
2007-03-28 |
2010-01-20 |
NeuroSearch AS |
Purinyl derivatives and their use as potassium channel modulators
|
|
KR101564233B1
(ko)
*
|
2007-03-28 |
2015-10-29 |
뉴로서치 에이/에스 |
푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도
|
|
US20090088403A1
(en)
*
|
2007-05-07 |
2009-04-02 |
Randy Blakely |
A3 adenosine receptors as targets for the modulation of central serotonergic signaling
|
|
WO2009052310A1
(en)
*
|
2007-10-16 |
2009-04-23 |
Cv Therapeutics, Inc |
A3 adenosine receptor antagonists
|
|
US8058259B2
(en)
|
2007-12-20 |
2011-11-15 |
University Of Virginia Patent Foundation |
Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
|
|
RU2451010C1
(ru)
*
|
2011-01-11 |
2012-05-20 |
Закрытое Акционерное Общество "Ива Фарм" |
Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
|
|
US9475797B2
(en)
|
2012-06-26 |
2016-10-25 |
Saniona A/S |
Phenyl triazole derivative and its use for modulating the GABAA receptor complex
|
|
WO2014138485A1
(en)
*
|
2013-03-08 |
2014-09-12 |
Irm Llc |
Ex vivo production of platelets from hematopoietic stem cells and the product thereof
|
|
CN110545822A
(zh)
|
2017-05-19 |
2019-12-06 |
全技术公司 |
药剂、组合物及其相关方法
|
|
CN113795267A
(zh)
|
2019-03-12 |
2021-12-14 |
艾库斯生物科学有限公司 |
致癌基因驱动的癌症的治疗
|
|
WO2020205527A1
(en)
|
2019-03-29 |
2020-10-08 |
Arcus Biosciences, Inc. |
Treatment of cancer utilizing an identified adenosine fingerprint
|
|
JP2022538409A
(ja)
*
|
2019-06-21 |
2022-09-02 |
アカデミー オブ ミリタリー メディカル サイエンシズ |
アデノシン化合物、その医薬的に許容可能な塩又はその立体異性体及びその使用
|
|
AU2021413448A1
(en)
*
|
2020-12-29 |
2023-07-20 |
Zhejiang Vimgreen Pharmaceuticals, Ltd |
Adenosine a3 receptor agonists, preparation methods and uses thereof
|